Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis

Clinical Rheumatology

Volumn 26, Issue 11, 2007, Pages 1871-1875

  Shinjo, Samuel K ^a   Pereira, Rosa M R ^a   Tizziani, Vivian A P ^a   Radu, Ari S ^a   Levy Neto, Maurício ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Glucocorticosteroid; Immunosuppressive drug; Mycophenolate mofetil; Takayasu Arteritis; Treatment

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CHLORAMBUCIL; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ADULT; AORTA ARCH SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; MALE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD SEDIMENTATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TAKAYASU ARTERITIS; TIME FACTORS;

EID: 34948846646     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0596-z     Document Type: Article

References (25)

1. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120:919-929 919-929
2. Hoffman GS, Ahmed AE (1998) Surrogate markers of disease activity in patients with Takayasu's arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 66:S191-S194
3. Daina E, Schieppati A, Remuzzi G (1999) Mycophenolate mofetil for the treatment of Takayasu arteritis: Report of three cases. Ann Intern Med 130:422-426
4. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296-2304
5. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129-1334
6. Hata A, Noda M, Moriwaki R, Numano F (1996) Angiographic findings of Takayasu arteritis: New classification. Int J Cardiol 54:S155-S163
7. Park MC, Lee SW, Park YB, Chung NS, Lee SK (2005) Clinical characteristics and outcomes of Takayasu's arteritis: Analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 34:284-292
8. Park MC, Lee WS, Park YB, Lee SK (2006) Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 45:545-548
9. Ito I (1992) Medical treatment of Takayasu's arteritis. Heart Vessels Suppl 7:133-137
10. Masmoudi S, Frikha I, Gdoura M, Zouari MH, Mnif J, Sahnoun Y (1992) Takayasu's disease. Diagnostic criteria and therapeutic procedure. Ann Cardiol Angiol (Paris) 41:A55-A61
11. Hoffman GS (1996) Takayasu's arteritis: Lessons from the American National Institutes of Health experience. Int J Cardiol 54:S99-S102
12. Numano F (2002) Takayasu's arteritis: Clinical aspects. In: Hoffman GS, Wyand CM (eds) Inflammatory diseases of blood vessels. Marcel Dekker, New York, pp 455-466
13. Hoffman GS, Leavitt RY, Kerr GS, Rottern M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistent or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578-582
14. Della Rossa A, Tavoni A, Merlini G, Baldini C, Sebastiani M, Lombardi M, Neglia D, Bombardieri S (2005) Two Takayasu arteritis patients successfully treated with Infliximab: A potential disease-modifying agent? Rheumatology (Oxford) 44:1074-1075
15. Johnston SL, Lock RJ, Gompels MM (2002) Takayasu's arteritis: A review. J Clin Pathol 55:481-486
16. Liang GC, Nemickas R, Madayag M (1989) Multiple percutaneous transluminal angioplasties and low dose methotrexate for Takayasu's arteritis. J Rheumatol 16:1370-1373
17. Besson-Léaud I, Grenier N, Besson-Léaud M, Boniface C, Guillard LM (2001) Takayasu's disease: Interest in methotrexate for Takayasu's arteritis. Arch Pediatr 8:724-727
18. Gutierrez-Urena MA, Molina JF, Garcia CO, Cuellar ML, Espinoza LR (1996) Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272-276
19. Shelhamer JH, Volkman DJ, Parillo JE, Lawley TJ, Johnston MR, Fauci AS (1985) Takayasu's arteritis and its therapy. Ann Intern Med 103:121-126
20. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477-484
21. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 30:1793-1798
22. Horigome H, Kamoda T, Matsuy A (1999) Treatment of glucocorticoid-dependent Takayasu's arteritis with cyclosporine. Med J Aust 170:566.
23. Haberhauer G, Kittl EM, Dunky A, Feyertag J, Bauer K (2001) Beneficial effects of leflunomide in glucocorticoid- and methotrexate-resistant Takayasu's arteritis. Clin Exp Rheumatol 19:477-478
24. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225-232
25. Kissin EY, Merkel PA (2003) Diagnostic imaging in Takayasu arteritis. Curr Opin Rheumatol 16:31-37